UniQure halves re­search, lays off 20% while CSO de­parts in ma­jor re­vamp

US and Dutch gene ther­a­py mak­er uniQure will un­der­go a broad over­haul that in­cludes lay­ing off 20% of its work­force, the de­par­ture of its chief sci­en­tif­ic of­fi­cer and a more than 50% slash­ing of re­search and tech in­vest­ment.

The moves come as gene ther­a­py com­pa­nies look for a way for­ward in the tough fi­nanc­ing en­vi­ron­ment and as oth­ers seek ex­its. The trans-At­lantic biotech ex­pects the prun­ing to save it $180 mil­lion over the next three years and take run­way in­to the sec­ond quar­ter of 2027. UniQure said 114 po­si­tions will be elim­i­nat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER